1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,239 | 0,309 | 19:17 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.07. | Sprint Bioscience AB: Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development | 236 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announced that it has entered into an agreement with Lilly TuneLab, a collaborative AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining... ► Artikel lesen | |
| 13.05. | Sprint Bioscience AB Q1 Loss Widens | 1 | RTTNews | ||
| 16.04. | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 261 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 205 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 240 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 269 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 1.044 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 10,360 | +1,77 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,690 | +9,58 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 91,14 | -1,09 % | Halozyme adds Dannielle Appelhans to board of directors | ||
| ABCELLERA BIOLOGICS | 9,910 | -3,79 % | AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity | ||
| GLOW LIFETECH | 0,027 | +55,88 % | Glow Lifetech Corp.: Glow Lifetech Announces Expansion into Quebec, Marking Significant New Market Opportunity in National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce its expansion into the Quebec cannabis... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 312,40 | +0,13 % | Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,180 | -9,92 % | BioLineRx Ltd. - 6-K, Report of foreign issuer | ||
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 4,000 | +4,88 % | Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway | ||
| WHITEHAWK THERAPEUTICS | 4,060 | -1,46 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026
Cash, cash equivalents and short-term... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 11,148 | +3,72 % | M Stanley Raises INNOVENT BIO TP to HKD138.5 on Strong 1H Product Revenue | ||
| OVID THERAPEUTICS | 2,300 | -5,74 % | Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA... ► Artikel lesen | |
| COCRYSTAL | 0,950 | +5,56 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| GEOVAX LABS | 0,608 | +2,22 % | EQS-News: GeoVax, Inc.: GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit 20.08.2026 / 15:03 CET/CEST
The issuer... ► Artikel lesen |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,004 (-1,43 %) liegt der Kurs bei 0,275 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.